INTRODUCTION:

In literature, vaccines are mainly produced or developed from pathogen components. Lot of efforts were taken to separate the components from pathogens and tried to increased its immunogenicity. In an attempt to isolate, purified and characterized the adjuvant for production of the vaccine. So, these adjuvant molecules mixed with pathogen components and may be responsible for reducing the burden of antigen in the vaccine and showing less side effects as compared to those vaccines having no adjuvant. In short, adjuvants are immunomodulators but all immunomodulators are not adjuvants but these adjuvant molecules may enhance depot effect, induction of CD8 T cell responses and showing excellent antigen presentation.¹

The mechanism of vaccines containing adjuvants are widely studied all over the world and suggest that adjuvant (e.g. alum) slowly release the antigen into the injection site, showed depot effect and thereby enhancing prolonged stimulation of the immune system. After immunizing the vaccine containing particulate adjuvant may have showed enhancement in pro-inflammatory response which is mainly confirmed through stimulation of innate immune cells (i.e. dendritic cells, connecting link between innate and adaptive immunity).^2,3 For these studies, various efforts were taken into consideration to understand the mechanism where adjuvants are responsible for enhancing the immunogenicity of vaccine. So, huge efforts were taken to produce adjuvants for vaccines and tried to understand their mechanism and then mixed with vaccine antigen and studied its potency test against several antigens.^1-3 So, various adjuvants were studied and showed some properties or characteristics (Fig.1) against several vaccine antigens and studied its various immunological properties as shown below-

Fig. 1: Characteristics of adjuvants for vaccine antigen

Alum adjuvant:

In terms of its resources, aluminium is among the three most widespread elements after silicon and oxygen, constituting up roughly 9 percent of the earth's crust. Air, water, soil, and plants all contain aluminium. While the majority of plants have small amounts of aluminium, some species of orchids, grasses, and tea plants are known to accumulate aluminium. Numerous commodities, such as pots and pans, foil, and storage containers like beverage cans, utilize aluminium significantly.^4,5Additionally, a variety of foods and beverages, such as honey, fruits and vegetables, beer and wine, spices, bread, cereals, nuts, and dairy products all contain aluminium. Adults typically consume 7 to 9 milligrams of aluminium each day.In the literature, vaccines contain aluminium as an adjuvant, which enhances the body's immunological response to the vaccination. Adjuvants enable the use of fewer doses and lower dosages of the vaccine.

In 1926, the adjuvant properties of aluminium were discovered. All live viral vaccinations, particularly those for varicella, rotavirus, measles, mumps, and rubella, do not include aluminium adjuvants.^4-6 Even though aluminium salts have been used as adjuvants for a relatively long time, questions remain regarding the specifics of their mode of action, and the results of some investigations seem inconsistent. For instance, several studies have shown that the effectiveness of an aluminium(hydroxide or phosphate, Fig.2) adjuvant is independent of the pace at which the antigen is delivered. It's possible that this is the result of the aluminium adjuvant's complex structure, which, like the transport framework, has no single constituent. As a result, various aluminium adjuvants may be produced in various ways or from various sources; they may also have various modes of action and provoke various immunological reactions.^7,8

Fig. 2: Alumnium hydroxide and Alumnium Phosphate

Before receiving a license, vaccines with adjuvants are put through a rigorous clinical study process. Adjuvants used in the US include aluminium salts, squalene (a byproduct of the body's natural cholesterol-making process), monophosphoryl A (a detoxified bacterial component), QS21 (which originates from Quillaja saponaria tree bark), CpG (nucleic acids), and monophosphoryl A (a detoxified bacterial component). The little dosages of aluminium required to undergo vaccinations have been recommended by the Centre for Biologics Evaluation and Research (CBER) for increasing humoral immunity.^9,10

Monophosphoryl Lipid A (MPLA,, Fig.3):

A modified form of the bacterial endotoxin lipopolysaccharide (LPS), MPLA is used as a vaccination adjuvant. Due to the significant focus on minimizing negative outcomes in preventive immunization, only a limited number of new adjuvants have been authorized for use in developed nations. Instead, the structure of MPLA appears to have coincidentally maintained various functions necessary for provoking adaptive immune responses while discarding those linked to undesirable inflammatory reactions. Researchers have examined LPS from various bacteria in order to encompass their endotoxic and immune-modulating characteristics. It is a harmless form derived from the lipid A portion of LPS. It is being formulated for use as both an adjuvant and a preventive treatment for septic shock.^11,
12 The recognition of LPS typically begins with the separation of LPS monomers from aggregates through the action of LPS-binding protein (LBP) present in the serum. CD14 accelerates the transfer of LPS from LBP to MD2, which is the component responsible for binding LPS in the receptor system. MD2 then generates the signaling functions of TLR4, a transmembrane protein of class

I.11-13.

Fig. 3: MPLA

Recent reports include two crystal structures of MD2: In the first, MD2 from humans has been shown to incorporate lipid IVa, a four-acylated LPS antagonist, whereas MD2 from mice is revealed to comprise eritoran, additional four-acylated antagonist. This complex forms a 1:1 ratio with the extracellular domain of TLR4. During the 1970s, Edgar Ribi methodically applied chemical alterations to LPS with the aim of investigating the potential separation of its beneficial immune-stimulating characteristics from its harmful endotoxic effects. Ultimately, Ribi developed a hydrolysis method that transformed LPS from Salmonella minnesota. This particular LPS consists of multiple acyl chains, three phosphates, and varying-length polysaccharide attachments linked to a di-glucosamine head group. The outcome of the process was a blend of acylated di-glucosamines, with the predominant variant featuring six acyl side chains, no polysaccharide extensions, and a single phosphoryl group.¹⁴The widely recognized monophosphorylated mixture is commonly referred to as MPL. However, for the sake of differentiation from the version produced by Glaxo Smith Kline, which is trademarked as MPL adjuvant, it is abbreviated as MPLA in this context. Ribi offers a diverse range of immunological products. An oil-in-water emulsion incorporating detoxified endotoxin (MPL) and mycobacterial cell wall components (TDW, CWS) along with 2% squalene is a key replacement for Freund's complete adjuvant made available by Ribi.^10-12This emulsion is comparable in convenience to Freund's complete adjuvant and is sometimes even more convenient due to its lower viscosity. It has minimal toxicity and has been administered to humans without issues. Ribi and colleagues assessed the toxicity and immunomodulatory capabilities of MPLA by determining the quantity required for lethality in chick embryos and for safeguarding against the proliferation of a tumor cell line implanted intradermally in a guinea pig tumor model. Their findings indicated that MPLA exhibited a toxicity level of at most 0.08% compared to its parent LPS, while displaying performance on par with, if not superior to, LPS in the tumor protection experiment.^11-13The conclusion drawn by Ribi and his co-workers was that MPLA, being a detoxified variant of LPS, preserved the majority, if not all, of the advantageous immunomodulatory functions of its parent compound.

RibiImmunochemicals, the company Ribi launched for the commercialization of MPLA, delivered MPLA as an essential part of the Ribi Adjuvant System. The resulting mixture, comprised of MPLA, trehalose, and oil, has already been commonly employed to generate monoclonal antibodies from test animals. The corporate entity Corixa Corporation and Glaxo Smith Kline Biologicals (GSK Biologicals) recently completed successive acquisitions of RibiImmunochemicals. GSK Biologicals essentially acquired Corixa for the purpose to get control of what it sees as the most important component for their accessible generation of vaccines. Pre-clinical rabbit pyrogenicity testing used for analysing the clinical-grade variant of MPLA, known as MPL adjuvantTM, found that it displayed roughly 0.1% of the toxicity revealed by LPS.¹⁶This outcome remarkably aligned with Ribi's initial approximations derived from assessments involving lethal chick embryo assays. It's noteworthy to emphasize that MPL adjuvant™ is primarily integrated into vaccine formulations in conjunction with other additives like alum, which enhance the physical administration of antigens. Currently, GSK Biologicals incorporates MPL adjuvant in several of its vaccine compositions.^11-13

MF 59 (Fig.4)

The oil-in-water emulsion adjuvant MF59 has been granted authorisation from a number of different nations worldwide usage in pandemic and seasonal influenza vaccinations.It has demonstrated safety and good tolerance in human subjects. The use of MF59 as an adjuvant in vaccinations conserves vaccine dosage and augments the production of hemagglutination inhibiting antibodies targeting both similar and dissimilar influenza virus strains.

Fig.4: MF59

MF59 operates by rapidly initiating chemokines, inflammatory cytokines, attracting a range of immune cells, as well as promoting uric acid accumulation and the harmless apoptosis of specific innate immune cells.¹⁴The development of antigen-specific IgG antibodies in multiple isotypes, effector CD8 T cells, and preventive immune system responses are all provoked by MF59's adjuvant attributes. By fostering advantageous immune-competent surroundings with an assortment of innate and antigen-presenting cells, MF59 preserves its adjuvant activities even in the presence of CD4 loss, evidenced in a mouse model. Children, the elderly, and those with impaired immune systems might gain advantages from vaccines more than healthy adults due to the CD4-independent adjuvant properties of MF59.^15,
16Strengthening the implementation of MF59 with additional vaccination antigens and populations while further investigating its adjuvant procedures require additional investigation. In 1997, the first seasonal influenza vaccination with MF59 adjuvant was granted approval, a first for the elderly. Since then, over thirty different countries, particularly the United States, have given approval for its use in human vaccinations. MF59-adjuvanted H1N1 pandemic influenza vaccines have been injected into a wide range of populations, including pregnant women and small children, in addition to its use in seasonal influenza vaccinations, and account for over 100 million doses.^14-16Improved immunogenicity of vaccines, specifically in the sense of developing hemagglutination-inhibiting antibodies while promoting the generation of memory T and B cells targeting influenza viruses that have gone through antigenic modifications, are some implications of the MF59 adjuvant on influenza vaccination. This results in pandemic and seasonal influenza vaccinations that are more effective. It has been shown that the lymph nodes' monocyte-derived dendritic cells (Mo-DCs) are stimulated to differentiate by MF59. These Mo-DCs were crucial because they were the main antigen-presenting cells (APCs) in charge of enhancing antigen-specific CD4 T cell responses.²¹ In mice, MF59 elevated the activation of CD4 T follicular helper cells and subsequently heightened the germinal center response, thereby augmenting B cell reactions. B cell responses following vaccination with subunit split viral or protein antigens necessitate CD4 T cells, which eventually culminates in a development of isotype-switched IgG antibodies.^14-17 A conventional perspective suggests that Adjuvants employed in vaccines trigger the innate immune system, a notably antigen-presenting cell (APCs), which in turn promotes the proper T helper cell responses, among which are Th1, Th2, and Th17, to be triggered. These T helper cell responses govern the quality and quantity of antigen-specific B cell responses, thereby shaping the outcomes of adaptive immunity. MF59 displays its adjuvant attributes by fostering the conversion of IgG isotypes and enhancing the adaptive immune response following vaccination, even when in a CD4-deficient state. This discloses an alternative strategy that goes above conventional CD4 T helper cell-dependent interprets for bridging the gap between innate and adaptive immune systems. It's noteworthy to note that although CD4 T cell support is not necessary, MF59's adjuvanticity depends upon its incorporation of major histocompatibility complex class II molecules (MHCII). The exact mechanisms underpinning the CD4-independent adjuvant effects of MF59 are yet to be fully elucidated.^14-17 In a mouse model, MF59-adjuvanted influenza vaccine demonstrated superior results when compared to alum. This was evident in terms of heightened levels of antigen-specific antibody generation, elevated HAI (hemagglutination inhibition) titers, and more effective protective outcomes.¹⁸Moreover, MF59 has exhibited enhanced adjuvant efficacy compared to alum when utilized with various vaccine antigens like tetanus toxoid, hepatitis B, as well as Group B and C Meningococcal bacteria, as observed in mice. In a mouse model, the influenza vaccine adjuvanted with MF59 generated increased amounts of antigen-specific antibodies, higher HAI titers, and provided superior protection compared to the alum-adjuvanted vaccine. Vaccination with MF59 adjuvant led to a 2 to 5 times increase in HAI titers compared to vaccination with alum adjuvant using an A/H5N1 influenza subunit vaccine. Low-dose influenza A/H5N1 vaccination with MF59 adjuvant resulted in elevated HAI titers compared to high-dose unadjuvanted vaccination.^14-18In both young to middle-aged (18−64 years) and older (≥ 65 years) adult populations, a single low-dose (3.75 µg) influenza A/H1N1 vaccine with MF59 adjuvant elicited optimal immune reactions, while higher doses of the vaccine combined with MF59 yielded the highest antibody titers. The MF59-adjuvanted influenza A/H1N1 vaccine, along with seasonal trivalent vaccines, presents advantages including conserving the antigen dose, provoking heightened antibody responses, extending antibody persistence, and amplifying the innate and adaptive immune responses in young children and adolescents. Aside from various age groups, the influenza vaccine enhanced with MF59 adjuvant displayed enhanced ability to provoke an immune response and achieve protective antibody levels in individuals with human immunodeficiency virus (HIV) infection and those with chronic kidney disease undergoing hemodialysis. This indicates a noteworthy positive impact of the MF59 adjuvant on the immune response of patients with compromised immune systems. MF59, an adjuvant approved for influenza vaccines, has been the subject of clinical trials for its application in enhancing other vaccines targeting various bacteria and viruses.^15-19 In a phase 2 trial, the combination of MF59 adjuvant with a subunit vaccine for human cytomegalovirus (HCMV) glycoprotein B exhibited an efficacy of approximately 50% in preventing HCMV acquisition. This positive outcome was attributed to the vaccine's ability to stimulate non-neutralizing antibody functions. Additionally, when MF59 was used as an adjuvant in Staphylococcus aureus vaccines, it prompted favorable immune responses involving both protective antibodies and cellular immunity in mice. Another instance involved an MF59-adjuvanted recombinant vaccine that integrated Aventis Pasteur's canarypox vector with HIV gp120. Although this vaccine couldn't postpone the onset of simian immunodeficiency virus infection in rhesus macaques, it did enhance the immune response to the vaccine antigen. Vaccines enhanced with MF59 adjuvant tend to stimulate immune responses that are skewed towards Th2 immunity. However, an even stronger Th1 cellular response to vaccination was induced when TLR9 agonist CpG or TLR4 agonist E6020 were added to MF59-adjuvanted vaccinations. This was characterized by elevated IgG2a levels, increased production of interferon-gamma, and comparable or higher antibody titers.^15-19

ASO1:

One among the many interesting patented adjuvant systems that have already been developed over the past 20 years comprises the adjuvant system AS01. MPL and QS-21 are two immune-enhancing components included in AS01, a liposome-based adjuvant (obtained by GSK under license from Antigenic Inc., a wholly owned subsidiary of Agenus Inc., a company with its headquarters in Delaware, USA). The effectiveness of AS01 in boosting adaptive immune responses relies on the combined and coordinated actions of QS-21 and MPL.²⁰The utilization of AS01 as an adjuvant holds promise for the development of novel vaccines intended for populations with intricate immune conditions, as well as for combating diseases triggered by intricate pathogens.

AS01 functions as a liposome-based adjuvant system for vaccines and includes two immune-boosting components: 3-O-desacyl-4ʹ- Monophosphoryl lipid A (MPL) and the saponin QS-21. Investigations into the mechanism of action of AS01 reveal that it generates swift and temporary effects, primarily in the muscle where it's administered and the associated lymph node. AS01 effectively stimulates immune responses mediated by CD4+ T cells, making it a suitable candidate for adjuvants in vaccines designed to target viruses or intracellular pathogens.^21,22 Additionally, this system has been studied for its role in amplifying immune reactions to specific antigenic components in potential vaccines aimed at malaria and herpes zoster. We particularly examine how AS01 contributes to augmenting precise immune reactions in relation to chosen potential vaccines designed to combat malaria and herpes zoster. AS01 additionally engages with the immune system by influencing the innate immune response. Preliminary research conducted in mice validates that the strength of subsequent adaptive immune reactions, both in terms of humoral and cell-mediated responses, is elevated when AS01 is administered alongside malaria and herpes zoster antigens, compared to when these antigens are introduced independently. AS01's impact on the innate response is notably efficient and effectively results in enhanced antigen-specific reactions.^21,22 Just like other adjuvants, AS01 induces a brief and localized activation of the innate immune system. However, AS01's innate response has distinctive aspects that differentiate it from other adjuvants. Notably, it lacks a prolonged depot effect, but it excels in prompting the activation of a diverse range of antigen-presenting cells (APCs), including classical dendritic cells (DCs) and DCs derived from monocytes. This is attributed to the collaborative action of MPL and QS-21, which results in heightened antigen-specific responses. Furthermore, AS01 steers the immune response towards a predominantly interferon (IFN)-driven pathway. This tendency for IFN might boost the cellular immune response and encourage an alteration in antibody isotypes. The reality that both the amount of cytokines and innate immune cell responses restore to normal by day 7 underscores the fleeting duration of AS01's impacts on the innate response in both the muscle and the draining lymph node. Recognizing the notable adaptive responses exhibited in human recipients of AS01-containing vaccinations is made clearer with assistance of careful examination of the innate reaction elicited by AS01/Ag in a mouse model. Candidates aiming for the treatment of malaria or herpes zoster fall underneath this.^{20- 22}

ASO3:

In an oil-in-water emulsion, -tocopherol, squalene, and polysorbate 80 are combined to form AS03, an adjuvant system. Through various clinical and nonclinical investigations, the administration of vaccines with AS03 as an adjuvant has yielded significant levels of antibodies specific to the antigen (Fig.5). This has allowed for strategies that conserve the antigen amount. AS03 has been demonstrated to amplify the adaptive immune response to the vaccine antigen by activating the innate immune system at the site of administration. Additionally, it enhances the uptake and presentation of the antigen in the lymph nodes that drain from the injection site.^23,24This process can be influenced by how much of -tocopherol in AS03. Enhanced concentrations of anti-influenza antibodies have been shown to be correlated with safeguarding towards illness and the development of influenza strains related and unrelated to the vaccination strain in studies utilizing nonclinical animals and the pre pandemic H5N1 influenza vaccine adjuvanted with AS03. When compared to vaccinations without adjuvants, the pandemic H1N1/2009 vaccine's immunogenicity was increased by the addition of AS03.

The efficacy of the H1N1/2009/AS03 vaccine was substantially proven across various assessments involving diverse populations. Collectively, the findings from both clinical and nonclinical research underline AS03's capacity to provoke enhanced adaptive responses to the vaccine antigen, primarily in terms of antibody levels and immune memory. In a broader sense, these outcomes support the idea of Adjuvant Systems as a viable strategy for developing new, efficacious vaccines. AS03 has been proven to induce transient innate immune responses dependent on NF-κB. This activation leads to the production of cytokines and chemokines at the injection site, which is typically the muscle, and in the draining lymph nodes.^23-25 This response prompts the recruitment of crucial immune cells like monocytes and granulocytes. In comparison to vaccines without adjuvants, AS03 enhances the scope and intensity of both cell-mediated and humoral immune reactions. AS03 stands apart from other oil-in-water adjuvants like MF59 due to its utilization of DL-α-tocopherol, a highly absorbable form of vitamin E. Both laboratory and live studies have reported that DL-α-tocopherol positively alters the character of the local innate immune response. This alteration contributes to an amplified antigen-specific antibody response, thereby enabling strategies that conserve the amount of antigen required for vaccination. Amid the influenza pandemic of 2009–2010, a vaccine that utilized adjuvant for dose conservation was advised for the majority of Canadians. Our proposition is that distinctions arise in the reactions to AS03-adjuvanted vaccines with low antigen (Ag) doses in comparison to unadjuvanted vaccines with full doses. Our study centers on exploring the correlation between the quantity of antigen and the oil-in-water emulsion Adjuvant System AS03.^25-28 In comparison to unadjuvanted "high-dose" immunization, both AS03A and AS03B-adjuvanted vaccines with lower antigen doses demonstrated a tendency to provoke elevated levels of serum antibodies, a wider spectrum of cytokine secretion, and resulted in the creation of a greater number of influenza-specific antibody-producing cells and cytokine-secreting CD4 and CD8 T cells within the spleen cells. Our study reveals that altering the antigen and/or AS03 dose within this mouse model for influenza vaccination can significantly impact the scale and profile of the immune response generated. These findings are notably pertinent considering the potential increase in the use of adjuvanted, dose-conserving vaccines and prompt questions regarding the application of "standard" vaccine doses in pre-clinical vaccine investigations. In a phase 1 and phase 2 experiment, the SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2 preSdTM) was previously investigated using several adjuvants and in both one-injection and two-injection dosing schedules. The two-injection schedule and the AS03 adjuvant have been picked for additional investigations based on the initial findings from that trial. However, the antibody responses, particularly in older persons, were less than predicted, and the reactogenicity after the second dosage was higher than planned. In the current study, we intended to assess both the safety and immunological response of a better CoV2 preSdTM vaccine formulation when adjuvanted with AS03. This evaluation had been carried out for providing valuable insights for the advancement of the vaccine into a phase 3 clinical trial.^23,24

Fig. 5: AS03 (an oil-in-water emulsion) and AS04 (aluminum and MPL)

ASO4:

AS04 is a novel adjuvant system known for enhancing the effectiveness of human vaccines, such as the HPV vaccine Cervarix, by combining MPL (3-O-desacyl-4'-monophosphoryl lipid A), a TLR4 agonist, with an aluminum salt (Fig.5). This study aims to uncover how AS04 works in human cells and mice. It was discovered that the adjuvant effect of AS04 is contingent on both AS04 and the HPV antigens being administered at the same intramuscular location within a 24-hour window.^{25, 26}AS04 merely promotes NF-kappaB activation and cytokine generation throughout this specific frame. As a result, there are additional monocyte and dendritic cells are among those which have been activated and loaded with antigen in the lymph node that have a connection to the injection site, which magnifies the activation of T cells that are selective for the antigen. Although AS04 had been demonstrated to stimulate these antigen-presenting cells in vitro, CD4 (+) T cells or B lymphocytes were not competitively stimulated by it. The substance AS04 is a combination of monophosphoryl lipid A (MPL), a TLR4 agonist, and aluminium hydroxide.^25-27With the use of in vivo tests on mice and in vitro examinations on human cells, the mechanism of action of AS04 has been effectively investigated. The molecular and cellular mechanisms that lie beneath both the effectiveness and protection of this formulation have gained greater clarity according to these results. In the present investigation, we explore how, based on the established mechanism of action, GlaxoSmithKline's clinical research on the AS04-adjuvanted HPV vaccine supports its immunogenicity, protective effects, and reactogenicity. The co-administration of AS04 with HPV antigens at the same intramuscular location during a 24-hour window was discovered to be significantly important for the adjuvant qualities of AS04, which result in an increased antibody response against HPV antigens. Coupling MPL with aluminium salt promotes immunological responses that are both humoral and cell-mediated. This occurred when a confined, transient cytokine response is promptly activated contributing to enhanced antigen-presenting cell proliferation and enhanced antigen presentation to CD4+ T cells.^25-28Clinical testing displaying robust vaccine-induced immune responses and the development of substantial quantities of memory B cells confirmed the MPL in AS04's essential benefit as an HPV vaccine. Particularly, the vaccine confers shielding against the following additional carcinogenic HPV subtypes that have been excluded in the vaccine itself: HPV-31, -33, and -45. The innate immune response is transitory and restricted, which helps explain why clinical tests have found an encouraging safety profile. The Adjuvant System 04 (AS04) and virus-like particles developed from the L1 protein of HPV-16 and HPV-18 have been merged to create a novel HPV vaccine. Due to the greater likelihood of human immunodeficiency virus (HIV) infection in regions with fewer amenities, the overall incidence of human papillomavirus (HPV) infection has possibly exacerbated there. The study covered the 72nd month of the trial period and evaluated the efficacy and safety of the HPV-16/18 AS04-adjuvanted vaccine in preteen and teenage girls for a period extending to 6 years following immunization. Clinical trials have confirmed the enhanced effectiveness of MPL in AS04 for an HPV vaccine. These trials revealed a robust production of antibodies and the development of substantial memory B cell levels in response to the vaccine. Additionally, the vaccination offers defense against a few additional carcinogenic HPV strains that are not incorporated into the vaccine formulation, especially HPV-31, -33, and -45. The innate immune response is transient and localized, which contributes to the good safety profile shown in clinical investigations.^25-28

CPG1018:

CpG ODN oligonucleotides have been demonstrated to be effective Th1-type adjuvants for boosting antigen-specific responses in mice against hepatitis B surface antigen (HBsAg). CpG 1018, which has undergone clinical research and has been formulated as an adjuvant for Dynavax's HEPLISAV-B Hepatitis B vaccine, has been shown in preclinical and clinical investigations to elevate antibody levels, activate both helper (CD4+) and cytotoxic (CD8+) T cell groups, and establish strong memory responses in both T and B cells.^29-31CpG 1018 adjuvant prominently promotes the formation of Th1 helper T cells, which are crucial for safeguarding against viral infections and intracellular bacteria. CpG 1018® specifically interacts with a single, clearly defined receptor known as TLR9, found on a limited number of important cell types. The mechanisms through which it acts as an adjuvant are thoroughly comprehended. The CpG 1018 adjuvant offers a mature technology and an extensive safety record, which could expedite the progress of new vaccine developments. CpG DNA has the capacity to stimulate the proliferation, differentiation, and activation of various immune cells, including B cells, natural killer cells, macrophages, and dendritic cells. It also enables these cells to take up and present antigens and to secrete a range of immunoglobulins, chemokines, and predominantly Th1-type cytokines. Studies conducted in mice and primates prior to clinical trials have demonstrated that DNA sequences containing CpG motifs can selectively enhance both cellular and humoral immune responses in living organisms.^29-31 Preliminary findings from ongoing clinical research indicate that CpG oligonucleotides (ODN) are well-tolerated and can enhance the immune response when used in combination with microbial vaccines. This study assesses the advancements made in incorporating CpG ODN as adjuvants in both traditional and DNA-based vaccines. The development of Th1 and pro-inflammatory cytokines, as well as the maturation and activation of specialized antigen-presenting cells, notably plasmacytoid dendritic cells, are all aided by CpG patterns. These effects are most effective when CpG ODN is in close physical proximity to the immunogen. When CpG ODN is co-administered with variousvaccines, it has been shown to enhance both humoral and cellular immune responses, leading to improved protective immunity in experimental challenges involving rodents and primates. Ongoing clinical investigations indicate that the use of CpG ODN as adjuvants in humans is safe and well-tolerated, while also demonstrating the ability to enhance vaccine-specific immune responses.^29-31

CONCLUSION:

Among the most effective tools available to humanity in the battle against infectious illnesses has been and still is vaccination. Humans have successfully eliminated the worst foes in human history from several regions around the globe, all because of these safe and efficient preventative measures. A vaccine's effectiveness is determined by the adjuvant's vital characteristics and role. Further research on these adjuvants is needed to develop increasingly safe and effective vaccines, which will have an impact on immunizations in the future. This objective is being pursued for the benefit of mankind via continual research and the examination of several items. After gaining a great deal of knowledge in the field of adjuvant research recently, vaccination effectiveness may now be increased by choosing an appropriate adjuvant rather than a traditional one, such as immune potentiators or mixtures of them. Lately, licences have been granted for the use of alum, MF59, AS03, CpG, and matrix-M in COVID-19 vaccine formulations globally.

REFERENCES:

1. Nugraheni RW. Yusuf H.Setyawan D. The Design of Liposomal Vaccine Adjuvant. Asian Journal of Pharmacy and Technology. 2017; 7 (4): 234-236. doi.org/10.5958/2231-5713.2017.00035.6.

2. Saha S. Roy A. Bahadur S.Chandrakar S. Choudhury A.Das S. Phytochemicals as Adjuvant in Neoplasia. Asian Journal of Research in Chemistry. 2014; 7(8): 765-770. doi.org/10.5958/0974-4150.

3. Stefano M. Beatrice M. Probiotics as adjuvant therapy in the treatment of Allergic Rhinitis. Research Journal of Pharmacy and Technology. 2023; 16(5): 2393-8. doi.org/10.52711/0974-360X.2023.00394.

4. Kumar SA.Venkatarathanamma V. Naga SV.Nageswara RT.Pavan KK. Kumar SK.Vijayalakshmi A. Anti-arthritic Activity of Annona squamosa Leaves Methanolic Extract on Adjuvant Induced Arthritis in Rats. Research Journal of Pharmacology and Pharmacodynamics 2017; 9(2): 46-56. doi.org/10.52711/0974-360X.2023.00394.

5. Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. The Journal of Clinical Investigation 2016; 126: 799–808. doi.org/10.1172/JCI81083

6. Ghimire TR. Benson RA. Garside P. Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunology Letters. 2012; 147: 55–62. doi.org/10.1016/j.imlet.2012.06.002.

7. Narendrakumar G.Dey R.Godavarthi SS.Preethi TV. Effect of Baculovirus with adjuvants against Helicoverpaarmigera (HBN) on Cotton and evaluation of its effect in Different Instar. Research Journal of Pharmacy and Technology. 2017; 10(7): 2111-2113. doi.org/10.5958/0974-360X.2017.00369.9.

8. Ananya KV.Patil AB. Gowda DV.Preethi S. Adjuvants employed in the Fabrication of sublingual vaccines. Research Journal of Pharmacy and Technology. 2020; 13(8): 3957-3962. doi.org/10.5958/0974-360X.2020.00700.3.

9. Chaudhary N.Weissman D. Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discovery. 2021; 20(11): 817–38. doi.org/10.1038/s41573-021-00283-5.

10. Jordan MB. Mills DM.Kappler J.Marrack P.Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science. 2004; 304: 1808–1810. doi.org/10.1126/science.1089926.

11. Evans JT.Cluff CW. Johnson DA. Lacy MJ. Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529. Expert Review of Vaccines (Second Edition). 2003; 2(2): 219–29. doi.org/10.1586/14760584.2.2.219.

12. Pouliot K.Buglione-Corbett R. Marty-Roix R.Montminy-Paquette S. West K. Wang S. Lu S. Lien E. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine. 2014; 32: 5049–5056.doi.org/10.1016/j.vaccine.2014.07.010.

13. Lilik M. Thomas VW.Nusdianto T.Suwarno.Koesnoto P. Nanda AN.Mahendra P.Zerlinda DA.Dita NP. Adjuvant Therapy of Syzygiumcumini Leaf and Fruit Extract Nanoparticles to Histopathological Changes of Mice Organ with Malaria. Research Journal of Pharmacy and Technology. 2022; 15(1): 389-394. doi.org/10.52711/0974-360X.2022.00064.

14. O’Hagan DT.Ott GS. De Gregorio E.Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012; 30:4341–4348. doi.org/10.1016/j.vaccine.2011.09.061.

15. O’Hagan DT.Ott GS. Nest GV.Rappuoli R.Giudice GD. The history of MF59 ((R)) adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines. 2013; 12: 13–30. doi.org/10.1586/erv.12.140.

16. O’Hagan DT.Rappuoli R. De Gregorio E. Tsai T. Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Review of Vaccines. 2011; 10:447–462. doi.org/10.1586/erv.11.23.

17. Cioncada R. Maddaluno M. Vo HTM. Woodruff M.Tavarini S.Sammicheli C.Tortoli M.Pezzicoli A. De Gregorio E. Carroll MC. et al. Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells. PLoS One. 2017; 12: e0185843. doi.org/10.1371/journal.pone.0185843

18. Ko EJ, Lee YT. Kim KH. Jung YJ. Lee Y. Denning TL. Kang SM. Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells. Journal of Virology. 2016; 90: 6976–6988. doi.org/10.1128/JVI.00339-16.

19. Nakaya HI. Clutterbuck E.Kazmin D. Wang L.Cortese M.Bosinger SE. Patel NB. Zak DE.Aderem A. Dong T.et al. Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci U S A. 2016; 113: 1853–1858. doi.org/10.1073/pnas.1519690113.

20. Chowdhury M. Kumar DP.Sekhar HM. Exploration of Basella alba mucilage as a novel adjuvant in Pharmaceutical Formulation. Research Journal of Pharmacy Technology. 2022; 15(6): 2609-2615. doi.org/10.52711/0974-360X.2022.00436.

21. Didierlaurent AM.Laupèze B. Di Pasquale A.Hergli N.Collignon C.Garçon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017; 16: 55–63. doi.org/10.1080/14760584.2016.1213632.

22. Leroux-Roels G.Leroux-Roels I. Clement F.Ofori-Anyinam O.Lievens M.Jongert E.Moris P. Ballou WR. Cohen J. Evaluation of the immune response to RTS, S/AS01 and RTS, S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults. Human Vaccines and Immunotherapeutics. 2014; 10: 2211–2219. doi.org/10.4161/hv.29375.

23. Morel S.Didierlaurent A. Bourguignon P.Delhaye S.Baras B. Jacob V.Planty C, Elouahabi A.Harvengt P.Carlsen H et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29: 2461–2473. doi.org/10.1016/j.vaccine.2011.01.011.

24. Lokhande SS. Microemulsions as Promising Delivery Systems: A Review. Asian Journal of Pharmaceutical Research.2019; 9(2): 90-96. doi.org/10.5958/2231-5691.2019.00015.7.

25. Garcon N et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs. 2011; 25: 217–226. doi.org/10.2165/11591760-000000000-00000.

26. Skinner SR. et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccines for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016; 15: 367–387. doi.org/10.1586/14760584.2016.1124763.

27. Naud PS. et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Human Vaccines and Immunotherapeutics. 2014; 10: 2147–2162. doi.org/10.4161/hv.29532.

28. Maskare RG.Indurwade NH.Deshmukh RA.Kuthe PV.Londhe PM.Deshmukh MT. Nanoemulsions: Increasing Possibilities in Oral Drug Delivery. Asian Journal of Pharmacy and Technology. 2021; 11(1):53-58.doi.org/10.5958/2231-5713.2021.00009.X.

29. Guiducci C et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006; 203: 1999–2008. doi.org/10.1084/jem.20060401

30. Hartmann G. Nucleic acid immunity. Adv Immunol. 2017; 133: 121–169.doi.org/10.1016/bs.ai.2016.11.001.

31. Kyriakidis NC. Lopez-Cortes A. Gonzalez EV.Grimaldos AB. Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021; 6(1):1–17. doi.org/10.1038/s41541-021-00292-w.

Received on 29.09.2023 Modified on 16.12.2023

Research J. Pharm. and Tech 2024; 17(7):3533-3540.

DOI: 10.52711/0974-360X.2024.00552